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S U M M A R Y
Dendritic cells (DCs) are specialized antigen presenting cells abundant in peripheral tissues such as skin
where they function as immune sentinels. Skin DCs migrate to draining lymph node where they interact
with naı¨ve T cells to induce immune responses to microorganisms, vaccines, tumours and self-antigens.
In this review, we present the key historical developments and recent advances in human skin DC
research. We also integrate the current understanding on the origin and functional specializations of DC
subsets in healthy skin with ﬁndings in inﬂammatory skin diseases focusing on psoriasis and atopic
eczema. A comprehensive understanding of the dynamic changes in DC subsets in health and diseasewill
form a strong foundation to facilitate the clinical translation of DC-based therapeutic and vaccination
strategies.
 2014 The Authors. Published by Elsevier Ireland Ltd. on behalf of Japanese Society for Investigative
Dermatology. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/3.0/).Contents
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Dendritic cells (DCs) are a heterogeneous population of
leukocytes that are critical in orchestrating immune responses.
In humans, the logistical difﬁculties of studying tissue DCs have led
to the extensive use of peripheral blood in vitromonocyte-derived
DCs (mo-DCs) as an experimental tool. The in vivo equivalent of
mo-DCs may be DCs seen in inﬂammation rather than healthy
tissue. The skin is an accessible epithelial barrier rich in antigen
presenting cells (APCs) and has been used as a model tissue to* Corresponding author at: Institute of Cellular Medicine, Newcastle University,
NE2 4HH, UK. Tel.: +441912227632.
E-mail address: m.a.haniffa@ncl.ac.uk (M. Haniffa).
http://dx.doi.org/10.1016/j.jdermsci.2014.08.012
0923-1811/ 2014 The Authors. Published by Elsevier Ireland Ltd. on behalf of Japanese
license (http://creativecommons.org/licenses/by/3.0/).study primary DCs in humans. In this review, we will outline the
current understanding of the composition, function and origin of
human skin DCs in health and two common inﬂammatory skin
diseases, psoriasis and atopic eczema.
2. Skin dendritic cells
The demonstration of MHC Class II, Fc and C3 receptors on
epidermal Langerhans cells (LCs) 109 years after their initial
discovery by Paul Langerhans in 1868, conﬁrmed their identity as
immune cells and promoted the use of human skin as a convenient
source to study tissue DCs [1–3]. These initial studies on murine
and human LCs formed the paradigm for ‘migratory’ tissue DCs
which sample antigen in their local microenvironment and
migrate to draining lymph node where they interact with TSociety for Investigative Dermatology. This is an open access article under the CC BY
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interrogation of DCs in the human dermis was undertaken by
immunostaining for Factor XIIIa (FXIIIa) which identiﬁed branch-
ing spindle shaped cells called ‘dermal dendrocytes’ [5]. This was
followed by the observation in 1993 that dermal myeloid DCs,
distinct from epidermal LCs, spontaneously migrated from skin
explants cultured ex vivo. Analysis of migrated cells identiﬁed two
dermal DC subsets characterized by the expression of CD1a and
CD14 [6,7]. However, in situ analysis of the human dermis revealed
CD1c+ DCs which co-express CD1a and FXIIIa+CD14+CD163+
dermal macrophages [8]. The puzzling observation of two myeloid
DCs within cells migrating spontaneously from skin explants but
only one subset identiﬁable in situ was explained by the
overlapping antigen proﬁle of CD14+ DCs with dermal macro-
phages. There are several features that distinguish CD14+ DCs from
macrophages: (1) morphology: macrophages contain dense
cytoplasmic melanin granules, (2) ﬂow cytometry: macrophages
have high scatter properties which result in autoﬂuorescence
easily identiﬁable in the FITC channel (excitation/emission: 488/
530(20)), (3) migratory behavior: only dermal CD14+ DCs migrate
spontaneously from skin explants cultured ex vivo, (4) adherence:
macrophages are adherent to tissue culture plastic and (5)
turnover kinetics: macrophages are reconstituted at a signiﬁcantly
slower rate by donor-derived cells following hematopoietic stem
cell (HSC) transplantation [9].
In addition to CD1c+ DCs and CD14+ DCs, CD141hi DCs were
recently identiﬁed in skin and other peripheral tissues [10]. Al-
though high expression of CD141 characterize this subset, this
antigen is also expressed by all CD14+ DCs and a subset of CD1c+
DCs [11]. An important distinction of CD141hi DCs from the other
DC subsets is the lack of CD14 expression and lower expression of
CD11c [10]. In the dermis, myeloid DCs are located more
superﬁcially than macrophages, which are present deeper and
primarily perivascular in distribution [12]. Whether the three
myeloid DC subsets occupy distinct microanatomical spaces is
unknown. Gene expression studies suggest that human skin
CD141hi DCs are homologous to murine CD103+/CD8+ DCs and
CD1c+ DCs are homologous to CD11b+CD24+CD64 DCs
(reviewed in [13]). Our recent analysis showed that dermal
CD14+ ‘DCs’ are monocyte-derived cells, which are transcrip-
tionally similar to FXIIIa+ macrophages [14]. In contrast to
myeloid DCs, plasmacytoid DCs (pDCs) are virtually undetectable
in healthy skin but are recruited during inﬂammation
[8,15,16]. pDCs are located in lymphoid tissues such as lymph
node and tonsil [17,18]. In addition to pDCs and tissue ‘migratory’
myeloid DCs, draining lymph node also contains ‘resident’
myeloid DCs. Lymph node ‘resident’ CD1c+ and CD141+ DCs
are HLADRlo and CD11chi, distinguishable from HLADRhiCD11clo
‘migratory’ DCs [10].
What is the biological need for different DC subsets? It is
important that division into DC subsets is not simply a trivial
classiﬁcation exercise. A considerable body of evidence has
accumulated over the years demonstrating specialized immune
functions for the various DC subsets. These studies have used
migrated primary cells or from enzymatically-digested skin and in
vitro CD34+ hematopoietic stem cell (HSC)-derived CD14+ DCs and
CD1a+ LCs [19–24]. A summary of the different functions described
for skin DC subsets can be found in Table 1.
A further consideration is the phenotypic stability of skin DCs.
DC subsets identiﬁed from enzymatic-digestion and spontaneous
migration have been shown to have similar antigenic proﬁle.
Although this suggests phenotypic stability, altered proportion of
DC subsets upon ex vivo cytokine treatments has been docu-
mented suggesting cellular plasticity [22,25,26]. Whether plas-
ticity within differentiated resident populations is an important
feature in vivo is uncertain. The demonstration of long-livedrecipient-derived macrophages after allogeneic HSC transplant,
despite the rapid repopulation of dermal DCs by donor-derived
cells, suggests that dermal macrophages do not differentiate into
resident skin DCs [9].
3. Origin of human skin dendritic cells
DCs arise from a bone marrow HSC-derived lineage dependent
on the receptor tyrosine kinase FLT3 [27–29] (Fig. 2). Patients
deﬁcient in blood monocytes and DCs due to IRF8 and GATA2
mutation lack dermal DC subsets, have reduced numbers of
macrophages but intact LCs [30,31]. This implies that dermal DCs
are directly dependant on circulating monocytes and/or DCs or a
shared HSC-derived precursor. In contrast, macrophages and LCs
are likely to arise from alternative precursors e.g. embryonic or
tissue-resident precursors, or are simply long-lived and turnover
very slowly. In mice, LCs were shown to arise from embryonic
progenitors which seed the skin prior to birth [32,33]. It is possible
that similar embryonic precursors directly contribute to human
LCs. Both human and murine LCs also possess local proliferative
potential [34,35].
The speciﬁc contributions of circulating blood DCs and
monocytes to skin DC subsets are still unclear. Human blood
DCs were identiﬁed in 1982 as cells expressing MHC Class II,
negative for lineage markers deﬁning T, B and NK cells (CD3, CD19,
CD20 and CD56) with potent allostimulatory properties
[36,37]. The LinClassII+ blood compartment contains human
monocytes and DC subsets, which all except pDCs, express the
integrin CD11c. Human monocyte subsets can be identiﬁed by the
expression of CD14 and CD16. DCs are found within the
CD14CD16 fraction and can be characterized by the expression
of CD1c and CD141/BDCA3 [38]. The phenotypic differences
between DCs initially identiﬁed in peripheral tissues (CD1c+ and
CD14+ ‘DCs’) and blood (CD1c+ and CD141+ DCs) was an obstacle to
establish their precise relationships easily. As skin CD14+ ‘DCs’ also
express CD141, which is further upregulated during spontaneous
migration from skin explant culture, it was initially thought to be
the equivalent of blood CD141+ DCs [11]. The identiﬁcation of
tissue CD14CD141hi DCs, distinct from CD14+ ‘DCs’ and CD1c+
DCs, corresponding to blood CD141+ DCs, has facilitated the
alignment of DC networks in peripheral blood and skin as shown in
Fig. 1. A proportion of cells within peripheral blood CD16+
monocyte population expressing 6-Sulfo LacNAc (SLAN), called
SLAN DCs, have also been described [39]. In healthy skin, SLAN+
cells have been found but unlike other DCs, do not express CD11c
[40].
The human and mice DC networks appears to be conserved
(Fig. 2) [10,41–46]. Inter-species homology predicts that the
human CD141+ DCs in blood and skin arise from a precursor that
precludes a monocyte stage. Blood CD141+ DCs upregulate CD1c
and CD1a upon co-culture with skin and express the the skin
homing receptor CLA suggesting that blood CD141+ DCs may be
the immediate precursors of skin CD141hi DCs [10]. Human
CD141+ and CD1c+ DCs possess a unique phenotype transcription
signature distinct frommonocytes andmacrophages. The murine
homologs of dermal CD14+ cells are dermal CD11b+CD64+
macrophages (Fig. 2).
4. Skin dendritic cells in inﬂammation and disease
The function of DCs as cutaneous sentinels and instigators of T
cell responses suggests a key role for these cells in inﬂammatory
skin diseases. We are beginning to understand the contribution of
DC to the pathogenesis of psoriasis and atopic dermatitis (AD). An
important consideration in studying DCs in inﬂamed skin is to
distinguish resident DCs that are normally present in skin from
Table 1
Functional studies on skin DC subsets.
Reference Subset Isolation and generation Function
Migrate Digest In
vitro
Cytokine Alloactivation Th2
polarization
Th1
polarization
Cross-
presentation
Cross-
priming
Memory/recall
response
Caux et al. [19] CD1a+ (CD1a+CD14-)  +++
CD14+ (CD1a-CD14+)  +++
Klechevsky et al. [20] LCs (CD1ahi CD14-HLA-DR+CD207+)  IL-15, IL-8 +++ +++ ++
CD14+ dDCs (CD1a-CD14+HLA-DR+)  IL-10, IL-6, MCP-1,
IL-12p40, IL-1b,
GM-CSF, TNFa
+ + ++
CD1a+ dDCs (CD1adim CD14-HLA-DR+)  IL-15, IL-8 ++ ++ ++
CD1a+ CD14- LCs  +++ +++ ++ +++ +++ ++
CD1a-CD14+ DCs  + ++ ++ + + +++
Morelli et al. [21] CD1a+CD14- LCs  IL-10, TGFb1 +++ ++ +++ +
CD1a-CD14- DDCs  IL-10, TGFb1 ++ ++ +++ +
CD1a-CD14+ preLCs  IL-10, TGFb1 + + ++
Angel et al. [23] dLCs (CD1ahi CD207+ CD14-) 
CD1a+ dDCs (CD1adim CD207- CD14-)  +++
CD14+ dDCs (CD1a-CD207- CD14+)  ++
Haniffa et al. [9] HLA-DR+CD14-CD1a+ dDCs  IL-1, IL-6, IL-23, IL-10 +++ +
HLA-DR+CD14+CD1a- dDCs  +
HLA-DR+CD14+CD1a-FXIIIa+ dMACs  IL-1, IL-6 +
Haniffa et al. [10] CD141 DCs (CD141hiCD11clo-intCD1clo)  TNFa, CXCL10 ++++
CD1c DCs (CD141loCD11chiCD1c+)  TNFa, IL-10, IL-8 +++
CD14+ DCs  IL-1b, IL-6, IL-8, IL-10 +
LCs  CXCL10, IL-8 +++
Matthews et al. [86] CD14+CD1a- migDCs  IL-6, IL-10, TNFa, IL-1b + +++ + +
CD1a+CD14- migDCs  IL-6 +++ + +++ +
CD14-CD1a- migDCs 
LCs  -
CD1a+ dDCs  -
Polak et al. [24] LCs  +++
CD11c+ dDC  +
Penel-Sotirakis et al. [87] LCs  TNFa, IL-6 +++ ++
CD1c+CD14- dDCs  TNFa, IL-6 ++ ++
CD14+ dDCs  TNFa + +
Fujita et al. [78] LCs (HLA-DR+CD207+)  +++ ++ ++
CD1c+ dDC (HLA-DRhiCD11c+1c+)  ++ + +
M
.
H
a
n
iffa
et
a
l./Jo
u
rn
a
l
o
f
D
erm
a
to
lo
g
ica
l
Scien
ce
7
7
(2
0
1
5
)
8
5
–
9
2
8
7
[(Fig._1)TD$FIG]
Fig. 1. Distribution of human dendritic cells, monocytes and macrophages in skin, blood and lymph nodes. Changes during inﬂammation are indicated in red text.
pDC = plasmacytoid DCs, Mac = macrophage, mono = monocytes, mo-Mac = monocyte-derived macrophage, inf DC = inﬂamatory DCs, IDEC = inﬂammatory dendritic
epidermal cell, TipDC = TNFa and iNOS producing DC.
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reasons: (i) there are no unique markers to identify recruited cells
and (ii) resident subsets may have an altered phenotype in
inﬂammatory environment. Furthermore, ‘snapshot’ analysis of
inﬂamed skin does not take into account the dynamic state of
migratory DCs which affects the nature and quantity of skin DCs at
a given time point during disease evolution. Functional differences
of DC subsets in inﬂammation may also be skewed by the tissue
microenvironment. In this section, wewill review the contribution
of DCs in psoriasis and AD pathogenesis with reference to these
difﬁculties.
4.1. Dendritic cell phenotype in inﬂamed skin
Animal models suggest that inﬂammation is accompanied by
monocyte-derived DC accumulation in tissues. Mice infected with
Listeria monocytogenes accumulate DCs in spleen. These DCs
produce TNFa and iNOS and are called TipDCs [47]. Inﬂammatory
DCs have also been described in a murine cutaneous Leishmania
model of skin inﬂammation [48]. In both models, inﬁltrating cells
express murine DC markers (CD11c, MHC II, CD80, CD86 and
DEC205) alongside monocyte (CD11b, Ly6C) and macrophage-
associated antigens (Mac-3, F4/80).A recent study on inﬂamed human synovial and ascitic ﬂuid
[49], compartmentswhere few resident cells are present in healthy
state, revealed inﬂammatory DCs which expressed HLA-DR, CD11c
and CD1c. These cells also express varying levels of CD1a, CD14,
CD206, FcER1 and SIRPa. It is difﬁcult to translate this ﬁnding into
skin where CD11c, HLA-DR and CD1c expression would also
identify resident dermal CD1c DCs. In psoriasis, DCs have been
recognized as a signiﬁcant proportion of inﬂammatory lesions
[50]. Chemerin production by dermal ﬁbroblasts, endothelial and
mast cells in psoriasis lesional and peri-lesional skin attracts pDC
in the initial stage of plaque formation [16]. The downstream
upregulation of Type I IFN genes results in subsequent myeloid
inﬂammatory DC recruitment [51,52]. Dermal CD11c+ cells in
psoriasis skin outnumber lymphocytes and coincide with areas of
TNFa and iNOS production [50]. The majority of CD11c+ cells
express high levels of HLA-DR as well as CD40 and CD86 [50]. By
immunohistochemistry, many CD11c+ cells are positive for SLAN
[53]. The absence of CD14, CD1c, CD1a and langerin distinguishes
these inﬂammatory DC from resident subsets. Co-localized
detection of TNFa and iNOS has lead to the suggestion that these
cells equate to TipDCs seen in murine models. Cells expressing
CD14 but lower levels of HLA-DR, in keeping withmonocytes, are a
small proportion of inﬂammatory lesions [50].
[(Fig._2)TD$FIG]
Fig. 2.Ontogeny of human andmouse dendritic cells in the steady state. Precursors,monocytes andDC subsets are annotated in black for human, and themouse homologs are
annotated in blue underneath the cell type. Question marks indicate unknown identity for the relevant species. Proven origin and relationships are indicated by solid arrows
and speculative relationships by dashed arrows. Functional properties of each dendritic cell subset are speciﬁed adjacent each cell type. HSC = hematopoietic stem cells,
MLP = mixed lymphoid progenitors, GMP = granulocyte macrophage progenitors, MDP = monocyte–macrophage/DC precursor, CDP = common DC precursor,
preDC = precursor of myeloid DC, pDC = plasmacytoid DCs, mac = macrophage, mono = monocytes and mo-Mac = monocyte-derived macrophage [88,89,90,91,92,93,94].
M. Haniffa et al. / Journal of Dermatological Science 77 (2015) 85–92 89In AD skin, CD1a+CD11b+CD1c+ myeloid DCs and pDCs [51,54–
56] have been observed. Both subsets express the high afﬁnity IgE
receptor, FcER1 [56]. Myeloid DCs isolated from AD epidermal
suspensions are called inﬂammatory dendritic epidermal cells
(IDEC) [57]. IDECs are distinct from resident Langerhans cells by
their lower expression of CD1a and lack of Birbeck granules, but it
is not clear how IDECs relate to dermal resident CD1c+ DC, which
can co-express CD1a and CD206.
4.2. Origins of inﬂammatory dendritic cells and their homeostasis in
inﬂammation
Although inﬂammatory skin lesions contain increased numbers
of DC, the precise origin of recruited DCs remains unclear. In
animal models, inﬂammatory DCs derive from the Ly6Chi mono-
cytes [47,48,58–60], which are equivalent to CD14 human
monocytes [61]. This differentiation is dependent on MyD88, a
key regulator of inﬂammatory cytokine signaling [62]. While
GMCSF is used in vitro to model inﬂammatory DC, its presence in
vivo is not essential for monocyte-derived inﬂammatory DC
differentiation [63]. Demonstrating cell ontogeny is more chal-
lenging in humans, but transcriptomic analysis showed that
inﬂammatory CD11c+HLA-DR+CD16CD1c+ DCs from synovial and
ascitic ﬂuids resemble in vitro mo-DCs [49]. However, convergent
genetic reprogramming can occur in both conventional andmo-DC
subsets upon microbial stimuli [64]. SLAN+TipDCs found in
psoriasis have been suggested to originate from blood SLAN+
DCs [53]. This conclusion is based on patterns of chemokine
receptors, cytokine production and margination of SLAN+ cells
along dermal capillaries. Analysis of cytokine production in amoDC model of IDECs supports their derivation from CD14
monocytes [65]. The contribution of blood or skin CD1c+ DCs,
which express FcER1, as precursors of IDECs has not been
evaluated. While it is clear that recruited cells are important for
the generation of inﬂammatory DCs, it is difﬁcult to ascertain the
precise contribution, if any, of in situ resident DC differentiation to
this pool.
During the inﬂux of monocytes to inﬂamed tissue, steady state
mechanisms of DC homeostasis are stressed and may lead to
alterations in resident population origin. An excellent example is
the differential precursor requirement for LCs in steady state and
inﬂammation. LCs are seeded from embryonic precursors during
foetal development and proliferate in quiescent skin to self-renew
[32,34]. However, during inﬂammation, LC may arise from
monocytes or bone marrow precursors and have an accelerated
turnover, as demonstrated by more rapid transition to donor-
derived LC in cutaneous graft versus host disease following bone
marrow transplantation [66–68]. In mice, tissue inﬁltration with
monocytes promotes monopoiesis at the expense of other myeloid
differentiation [69]. Skewing of myeloid development pathways
has not been demonstrated in humans, but may have signiﬁcant
effects in chronic inﬂammation. Insufﬁcient replacement of
resident DCs could contribute to loss of tolerance and secondary
infection.
4.3. Functional properties of dendritic cells in inﬂammation
Inﬂammatory DCs contribute to beneﬁcial immune responses
in murine infectious models. The TipDCs in murine L. mono-
cytogenes infection model have allostimulatory capacity in mixed
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T cell priming in vivo. Their beneﬁcial role in clearing bacteria is
attributed to TNF and iNOS production [47]. However, inﬂamma-
tory DC in murine cutaneous Leishmaniasis do prime naı¨ve T cells
and contribute to pathogen-clearing Th1 responses in vivo
[48]. Protective CD8, and Th2 responses have been demonstrated
in inﬂuenza, vaccination and sensitization models respectively
[59,70,71]. Inﬂammatory DC may also shape adaptive immunity in
situ by activating tissue-resident effector memory T cells [72].
Current understanding of psoriasis reveals multiple contribu-
tions by DCs in disease pathogenesis. IFNa produced by pDCs
during initial plaque formation [52] leads to IL-23 and IL-17
upregulation in the skin. IL-23 polarizes Th17 cell differentiation
and also potentiates IL-17 production by a variety of immune cells
such as neutrophils, mast cells and gd T cells in psoriasis lesion
[73]. The genetic association with the IL-23/Th17 pathway and the
efﬁcacy of anti-IL-23 and anti-IL-17 therapies support the
importance of IL-23 and IL-17 in psoriasis pathogenesis [50,74]. Re-
cent reports show that anti-TNFa therapy may also target IL-23
and IL-17 pathway in clearing psoriasis [75]. DCs in normal and
psoriasis skin are capable of producing IL-23 [76]. In addition,
SLAN+TipDCs found in psoriasis skin have been shown to prime
naı¨ve T cells to produce Th1/17 cytokines [77] similar to DCs from
inﬂammatory ﬂuids [49]. The expression of Th1 and Th17
recruiting chemokines CXCL1, CXCL8 and CCL20 is upregulated
in psoriasis skin but the precise contribution of DCs to chemokine
secretion in psoriasis is unknown [78]. Interestingly, the observa-
tion that peri-lesional psoriasis skin spontaneously develops into
psoriasis plaque following engraftment onto mice suggests that
skin resident leukocytes alone are sufﬁcient for disease manifes-
tation [79]. How skin DCs directly modulate resident T cells in
lesional skin warrants further exploration.
Disruption of skin barrier function due to ﬁlaggrin deﬁciency is
an important predisposing factor for AD [80]. The barrier-
breakdown signal, TLSP, is produced by keratinocytes and is
critical in the pathogenesis of AD (reviewed in [81]). TSLP-
activated DCs have been shown to be potent stimulators of naı¨ve T
cells and drive Th2 cytokine production. LCs which are in the
appropriate anatomical compartment have been shown to be TSLP
responsive [82]. Th2 producing lymphocytes are recruited to tissue
via CCL17, CCL18 and CCL22 signaling [78]. These chemokines have
been detected in myeloid DCs and LCs in AD skin [78]. Th22
cytokines also feature in AD lesions, and their production can be
stimulated by pDCs [83,84]. Crosslinking IgE is important in later
stages of AD pathogenesis and its high afﬁnity receptor, FcERI, is
expressed by LCs, IDECs and pDCs [55,56]. FcERI-activation of both
in vitro-derived LCs and IDECs yields a proinﬂammatory response
[85].
Although it is clear that the skin APC compartment expands in
psoriasis and AD, the subsequent fate of APCs during disease
progression and inﬂammation resolution is unknown. There is
little evidence that inﬂammatory DCs in psoriasis and AD migrate
into lymphatics or re-enter blood circulation. Alternative possibil-
ities include cell death in the skin or differentiation into a resident
subset.
5. Conclusion
The human skin has a rich network of DCs which are
heterogeneous and functionally specialized. Recent progress in
distinguishing DC subsets from resident macrophages and the
characterization of the dynamic populations in inﬂammatory
states has begun to shed light on their role in skin homeostasis and
pathology. An enhanced understanding of skin DCs origin,
homeostasis, function and pathogenic role in disease will provide
novel avenues to be exploited for clinical therapy.Funding
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